New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
15:43 EDTVRX, AGNPaulson & Co accumulates over 6M shares of Allergan, Reuters says
Paulson & Co accumulates over 6M shares of Allergan (AGN), supporting deal with Valeant (VRX), says Reuters.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
September 28, 2015
16:23 EDTAGNAllergan sees 10% branded revenue growth after divestiture of generics unit
Following the close of the divestiture of the Generics business to Teva (TEVA), New Allergan (AGN) expects to have a powerful financial profile to drive continued long-term growth: 10% branded revenue growth; Non-GAAP gross margins of 77% to 79% with additional long-term expansion anticipated; Non-GAAP SG&A as a percentage of revenue between 21-24%, declining within that range over time; Non-GAAP tax rate of ~15%; Interest expense for New Allergan will be largely dependent on capital deployment decisions following the close of the transaction; Commitment to investment grade ratings. "New Allergan will have strong double-digit revenue growth and will be a development powerhouse stacked with 70 mid-to-late stage R&D projects to address customer and patient needs," said Brent Saunders, CEO and President. "The New Allergan will be lean and nimble with an expanded margin profile driven by leading brands in seven therapeutic categories, a streamlined operating model with one of the most efficient SG&A as a percentage of sales in the industry, a non-GAAP tax rate of approximately 15 percent, and a simplified manufacturing network globally. The continued robust performance of our overall business and strong mid-to-late stage pipeline puts Allergan in a strong position to meet our growth targets for the remainder of the year and over the long-term."
16:21 EDTAGNAllergan sees 2H15 adjusted EPS $6.25-$6.65
Subscribe for More Information
16:19 EDTVRXOn The Fly: Top stock stories for Monday
Stocks on Wall Street were sharply lower as investors continue to worry about the health of China's economy and continue to flee the biotech sector. The iShares NASDAQ Biotechnology Index (IBB) was down 6.33% today and is down about 18.5% since September 21, when Democratic presidential candidate Hillary Clinton pledged to take action against the high prices of specialty drugs. Adding to the tentative mood among investors was noted investor Carl Icahn's preview for a presentation that will be made available on his site tomorrow, entitled "Danger Ahead." The preview includes several cautious comments that the billionaire has publicly made recently regarding his concerns about the high-yield bond market and the stock market. ECONOMIC EVENTS: In the U.S., personal income grew 0.3% in August, versus expectations for it to rise 0.4%. Personal spending rose 0.4% last month, versus expectations for growth of 0.3%. The pending home sales index fell 1.4% in August, missing expectations for it to have risen 0.4%. The Dallas Fed manufacturing outlook survey for September had a reading of -9.5, versus expectations for a reading of -10.0. In China, industrial profits plunged 8.8% in August, adding to the recent string of weak data from the Asian giant. COMPANY NEWS: Apple (AAPL) reported that it set a record by selling more than 13M new iPhone 6s and iPhone 6s Plus models in the first three days after launch of the devices. However, shares of the tech giant slid about 2% to $112.44 following the announcement... Alcoa (AA) shares advanced 52c, or 5.73%, to $9.59 after the company announced that its board has approved a plan to separate into two independent, publicly-traded companies - an Upstream company that will operate under the Alcoa name and a new "Value-Add company" that will provide high-performance, multi-material products whose name will be announced at a later date... Biotech stocks continued recent declines, with Valeant (VRX) dropping 16.6% after a group of Democratic congressmen urged additional scrutiny of the company's "price hike" business model, while Epizyme (EPZM) and NewLink (NLNK) fell a respective 27% and 21% after presenting data at the 2015 European Cancer Congress... Shares of both Energy Transfer Equity (ETE) and Williams (WMB) fell after they announced a combination deal valued at approximately $37.7B, including the assumption of debt and other liabilities. Under the terms of their deal, an affiliate of ETE will acquire Williams at an implied current price of $43.50 per Williams share, the companies said. In late June, Energy Transfer Equity made a proposal to merge with Williams in an all-equity transaction valued at that time at $53.1B, including the assumption of debt and other liabilities. Under that prior merger proposal, ETE would have acquired all of the outstanding common stock of Williams at an implied price of $64 per Williams share, which represented a 32.4% premium to Williams' common share closing price as of June 19. Energy Transfer Equity shares closed down $2.95, or 12.69%, to $20.29 after announcing today's revised deal, while Williams dropped $5.03, or 12.09%, to close at $36.57. MAJOR MOVERS: Among the notable gainers was Republic Airways (RJET), which surged $2.38, or 81.8%, to $5.29 after announcing that the company and Teamsters Local 357 have reached a consensual tentative agreement on the terms of a new three-year contract for the 2,100 Republic pilots represented by the International Brotherhood of Teamsters. Also higher was Media General (MEG), which gained $2.49, or 22.3%, to $13.64 after Nexstar (NXST) proposed a cash-and-stock deal to acquire the company for $14.50 per share, which Media General said it would "carefully review." Additionally, Sanchez Energy (SN) rose 4.5% to $5.57 after agreeing to sell certain Eagle Ford Shale midstream assets to Sanchez Production Partners (SPP) for $345M. Among the noteworthy losers was Huntsman (HUN), which plunged $3.99, or 28.7%, to $9.92 after warning that headwinds would impact its third quarter earnings. Also lower were shares of Depomed (DEPO) and Horizon Pharma (HZNP), falling a respective 22% and 21%, after Depomed continued its criticism of Horizon's hostile takeover bid for the company. INDEXES: The Dow fell 312.78, or 1.92%, to 16,001.89, the Nasdaq lost 142.53, or 3.04%, to 4,543.97, and the S&P 500 dropped 49.57, or 2.57%, to 1,881.77.
14:38 EDTVRXValeant crashes after Democrats push for subpoena
Shares of Valeant Pharmaceuticals (VRX) continued their week-long descent on Monday after a group of Democratic congressmen urged additional scrutiny of the company's business model. GOVERNMENT SCRUTINY: Eighteen Democratic congressional representatives requested that the House Oversight Committee subpoena Valeant for information related to allegedly "massive" price increases for two cardiac drugs recently acquired by the company. Referencing recent controversy surrounding Turing Pharmaceuticals, this morning's letter to the committee said "Valeant is using precisely the same business model as Martin Shkreli... whose company recently purchased the life-saving drug Daraprim and increased the price from $13.50 to $750 per pill... Similarly, in February, Valeant purchase the rights to sell Nitropress... and Isuprel... The same day, Valeant increased the prices of these drugs to $805.61 and $1,346.62, respectively, [representing] increases of 212% and 525%." In addition to the subpoena, the congressmen also requested that the committee invite Valeant CEO Mike Pearson to testify along with Martin Shkreli, "since both appear to be engaging in the same business model." Note that today's news follows an August 15 letter to Valeant from Senator and Presidential candidate Bernie Sanders and Rep. Elijah Cummings, who requested similar information related to what they called "artificially inflated" drug prices. Valeant rejected that request, citing confidentiality concerns. CEO RESPONSE: On Monday, Valeant distributed a letter to employees from its Chief Executive Mike Pearson. Responding to what he called "two main issues worrying investors," Pearson claimed "Valeant is well-positioned for strong organic growth, even assuming little to no [drug] price increases... We have consistently pursued profitable growth through diversification, strong execution and financial discipline while minimizing exposure to governmental policy changes and volatility." PRICE ACTION: Shares of Valeant Pharmaceuticals are down more than 15% to trade near $167 this afternoon. The stock has fallen roughly $78 from the $245 per share price it reached intraday on September 21, which is the day when Turing Pharmaceuticals' Daraprim price hike made headlines and prompted Presidential candidate Hillary Clinton to criticize the "outrageous" prices of specialty drugs and lay out a plan to combat the problem. Biotech stocks are broadly lower since that time as well, as the iShares NASDAQ Biotechnology Index (IBB) is down 6% today and down about 19% since September 21.
13:50 EDTVRXCitron Research sets $130 short-term price target on Valeant
After House Democrats asked to subpoena Valeant for documents relating to drug price increases, Citron Research tweeted that it puts a $130 short-term price target on the stock. Reference Link
13:49 EDTVRXValeant puts active after House Democrats seek subpoena
Subscribe for More Information
13:29 EDTVRXValeant sinks after House Democracts seek subpoena, Bloomberg reports
Valeant Pharmaceuticals shares are plunging after House Democrats asked to subpoena the company for documents relating to drug price increases, Bloomberg reports. In midday trading, shares of Valeant are down 13% to $173.75. Reference Link
12:49 EDTVRXValeant down 10% after Democrats request subpoena
Subscribe for More Information
12:45 EDTVRXHouse Democrats urge Valeant to turn over documents, Bloomberg says
11:28 EDTVRXValeant mentioned cautiously in a Seeking Alpha article
Reference Link
10:20 EDTVRXOptions with increasing implied volatility
Subscribe for More Information
08:24 EDTVRXValeant CEO tells employees bear thesis in media incorrect
Valeant Pharmaceuticals disclosed that it distributed a letter today from its CEO Michael Pearson to employees relating to recent changes in Valeant's stock price. The letter stated in part, "A number of you have asked me and other senior members of our management team about the significant drop in our stock price - especially over the past 5 trading days. While the entire pharmaceutical and biotech sector has been impacted by market volatility and numerous press articles about pharmaceutical pricing, we have been hit particularly hard. After talking with a number of investors and observing the concerns and assertions in the media, I thought it would be helpful to give you my perspective on the two main issues worrying investors: 1) Concern that our business model and strategy is dependent upon large price increases in our U.S. pharmaceutical business, 2) Concern around our exposure to U.S. government drug price reimbursement. I can assure you that this bear thesis is incorrect on both accounts...Turning to the first concern about our business model, the majority of our portfolio will continue to deliver strong volume-based organic growth and is not dependent on price increases...Turning to the second concern about proposed changes to government reimbursed products in the U.S., our exposure to U.S. government reimbursement currently represents approximately 15% of our total revenue. Of this, about one third, or ~5%, represents sales to Medicaid, the Department of Veterans Affairs, the Department of Defense, and other government entities, where the business is at best marginally profitable. Despite this, we continue to offer our products through these programs to ensure these patients continue to have access to needed medications. The remaining 10% of our government exposure is related to Medicare. As I stated above, our overall strategy is to focus on private and cash pay markets and to minimize government reimbursement. I believe our exposure to government reimbursement is lower than any other major pharmaceutical company." Shares of Valeant are down 18% over the past five trading days. They closed Friday down $10.18 to $199.32.
07:52 EDTAGNIIR Holdings to hold a conference
Subscribe for More Information
07:46 EDTVRXUBS to hold a field trip
Subscribe for More Information
September 25, 2015
12:38 EDTVRXOptions with increasing implied volatility
Subscribe for More Information
08:00 EDTAGNAllergan launches generic version of INVEGA
Allergan announced that it has launched a generic version of Janssen's INVEGA in the U.S. Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA, demonstrating the deep expertise of the Company's global generics R&D, regulatory and supply chain teams.
05:11 EDTVRXStocks with implied volatility movement; VRX CAT
Subscribe for More Information
September 24, 2015
14:17 EDTAGNAppeals court affirms Shire Vyvanse patents valid until 2023
Subscribe for More Information
11:08 EDTVRXOptions with increasing implied volatility
Options with increasing implied volatility: PTCT CZR KITE HZNP NAV CREE VRX PNK
September 23, 2015
09:05 EDTAGNAmgen and Allergan's lung cancer biosimilar candidate meets Phase 3 endpoints
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use